Sona Nanotech initiates clinical trial for Hyperthermia Therapy in advanced Melanoma patients

Sona Nanotech CEO David Regan joined Steve Darling from Proactive at a key BioTech conference in Boston to announce a significant milestone for the company in the development of its innovative cancer treatment technology. Sona has officially entered into a clinical trial agreement with Bradford Hill in Chile to conduct an early feasibility study of its Targeted Hyperthermia Therapy, focusing on patients with advanced melanoma.

The study will enroll up to ten patients who have previously been treated with, but failed to respond to, standard immunotherapy protocols. The trial is designed to assess the safety, tolerability, and preliminary efficacy of Sona’s THT approach. Each participant will receive two treatments spaced one week apart, applying Sona’s novel photothermal therapy to hard-to-treat tumors.

Pending final ethics committee approval, patient enrollment is expected to begin by the end of June, with interim results anticipated later this summer and final results projected for fall 2025. Regan emphasized that this feasibility study will play a crucial role in advancing the clinical development of THT, providing the first in-human data to support its future application across broader patient populations and cancer types.

Sona’s Targeted Hyperthermia Therapy is a cutting-edge photothermal cancer treatment that uses gold nanorods to deliver heat directly to solid tumors. These nanorods are introduced into the tumor site, where they absorb infrared light, converting it into localized therapeutic heat that can help destroy cancerous tissue without harming surrounding healthy cells.

Regan noted that the company is optimistic about the study’s outcomes and sees this trial as a potential catalyst for broader clinical adoption, strategic partnerships, and future regulatory submissions. With early results expected in just a few months, Sona Nanotech is well-positioned to advance its mission of transforming cancer treatment through targeted nanotechnology-driven therapies.

#proactiveinvestors #sonananotechinc #cse #sona #otcqb #snanf #CancerTherapy #GoldNanorods #FDAApproval #BiotechNews #Immunotherapy #ClinicalTrials #Nanomedicine #DrugSafety #CancerTherapy #TargetedHyperthermia #ClinicalTrials #MelanomaTreatment #BiotechNews #MedicalDevices #Immunotherapy #HealthcareInnovation #ProactiveInvestors